Literature DB >> 10426314

Hepatitis B virus transgenic mouse model of chronic liver disease.

J Larkin1, M Clayton, B Sun, C E Perchonock, J L Morgan, L D Siracusa, F H Michaels, M A Feitelson.   

Abstract

A model for hepatitis B virus-associated chronic liver disease has been made using cloned hepatitis B virus DNA as a transgene in a severe combined immunodeficient host. These mice consistently support virus gene expression and replication. After adoptive transfer of unprimed, syngeneic splenocytes, these mice cleared virus from liver and serum, and developed chronic liver disease. This model will permit identification of the host and virus contributions to chronic liver disease in the absence of tolerance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10426314     DOI: 10.1038/11347

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  22 in total

1.  Establishment of transgenic mouse harboring hepatitis B virus (adr subtype) genomes.

Authors:  Y P Hu; W J Hu; W C Zheng; J X Li; D S Dai; X M Wang; S Z Zhang; H Y Yu; W Sun; G R Hao
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

2.  Humanized murine model for HBV and HCV using human induced pluripotent stem cells.

Authors:  Xiao-Ling Zhou; Gareth J Sullivan; Pingnan Sun; In-Hyun Park
Journal:  Arch Pharm Res       Date:  2012-02-28       Impact factor: 4.946

Review 3.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Antiviral treatment of hepatitis B virus-transgenic mice by a marine organism, Styela plicata.

Authors:  Rui Wang; Zhen-Lan Du; Wen-Jun Duan; Xin Zhang; Fan-Lin Zeng; Xin-Xiang Wan
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

5.  Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly.

Authors:  Guoyi Wu; Bo Liu; Yingjun Zhang; Jing Li; Alla Arzumanyan; Marcia M Clayton; Raymond F Schinazi; Zhaohe Wang; Siegfried Goldmann; Qingyun Ren; Faxhou Zhang; Mark A Feitelson
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

6.  The hepatitis B virus core promoter is strongly activated by the liver nuclear receptor fetoprotein transcription factor or by ectopically expressed steroidogenic factor 1.

Authors:  S Gilbert; L Galarneau; A Lamontagne; S Roy; L Bélanger
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 7.  Liver immune-pathogenesis and therapy of human liver tropic virus infection in humanized mouse models.

Authors:  Moses T Bility; Feng Li; Liang Cheng; Lishan Su
Journal:  J Gastroenterol Hepatol       Date:  2013-08       Impact factor: 4.029

8.  Establishment and primary application of a mouse model with hepatitis B virus replication.

Authors:  Feng-Jun Liu; Li Liu; Fang He; Su Wang; Tao-You Zhou; Cong Liu; Lin-Yu Deng; Hong Tang
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

9.  Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-beta-L-glyceropent-2-enofuranosyl)cytosine.

Authors:  Huachun Chen; S Balakrishna Pai; Selwyn J Hurwitz; Chung K Chu; Yuliya Glazkova; Harold M McClure; Mark Feitelson; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  Inhibitory effect of oxymatrine on serum hepatitis B virus DNA in HBV transgenic mice.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Jing-Yuan Fang; Yu-Lin Song; Zhao-Hui Shen; Ai-Ping Cao
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.